# HMG-I/HMG-Y siRNA (h): sc-37115



The Boures to Overtion

#### **BACKGROUND**

High mobility group (HMG) chromatin proteins bind to the minor groove of AT-rich DNA sequences with high affinity. Evidence suggests that the binding of HMG proteins to DNA induces alterations in the DNA architecture including DNA bending and unwinding of the helix. HMG proteins synergize with Oct-2, members of the NF $\kappa$ B family, ATF-2 and c-Jun to activate transcription. Other studies indicate that phosphorylation of HMG protein is required to stimulate the transcriptional activity of the protein. Human HMG-I/HMG-Y contains two DNA-binding domains, termed HMG boxes. HMG proteins bind single-stranded DNA but induce conformational changes in double-stranded DNA alone.

# **CHROMOSOMAL LOCATION**

Genetic locus: HMGA1 (human) mapping to 6p21.31.

#### **PRODUCT**

HMG-I/HMG-Y siRNA (h) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10  $\mu$ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see HMG-I/HMG-Y shRNA Plasmid (h): sc-37115-SH and HMG-I/HMG-Y shRNA (h) Lentiviral Particles: sc-37115-V as alternate gene silencing products.

For independent verification of HMG-I/HMG-Y (h) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-37115A, sc-37115B and sc-37115C.

# STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330  $\mu$ l of the RNAse-free water provided. Resuspension of the siRNA duplex in 330  $\mu$ l of RNAse-free water makes a 10  $\mu$ M solution in a 10  $\mu$ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

## **APPLICATIONS**

HMG-I/HMG-Y siRNA (h) is recommended for the inhibition of HMG-I/HMG-Y expression in human cells.

## **SUPPORT REAGENTS**

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10  $\mu$ M in 66  $\mu$ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

#### **GENE EXPRESSION MONITORING**

HMG-I/HMG-Y (D-12): sc-393213 is recommended as a control antibody for monitoring of HMG-I/HMG-Y gene expression knockdown by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) or immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-lgG $\kappa$  BP-HRP: sc-516102 or m-lgG $\kappa$  BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker<sup>TM</sup> Molecular Weight Standards: sc-2035, UltraCruz<sup>®</sup> Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use m-lgG $\kappa$  BP-FITC: sc-516140 or m-lgG $\kappa$  BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz<sup>®</sup> Mounting Medium: sc-24941 or UltraCruz<sup>®</sup> Hard-set Mounting Medium: sc-359850.

# **RT-PCR REAGENTS**

Semi-quantitative RT-PCR may be performed to monitor HMG-I/HMG-Y gene expression knockdown using RT-PCR Primer: HMG-I/HMG-Y (h)-PR: sc-37115-PR (20  $\mu$ I, 527 bp). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

#### **SELECT PRODUCT CITATIONS**

- Gasparini, G., et al. 2012. Functional relationship between high mobility group A1 (HMGA1) protein and Insulin-like growth factor-binding protein 3 (IGFBP-3) in human chondrocytes. Arthritis Res. Ther. 14: R207.
- 2. Arcidiacono, B., et al. 2015. Cooperation between HMGA1, PDX-1, and MafA is essential for glucose-induced Insulin transcription in pancreatic  $\beta$  cells. Front. Endocrinol. 5: 237.
- 3. Chiefari, E., et al. 2016. A polymorphism of HMGA1 protects against proliferative diabetic retinopathy by impairing HMGA1-induced VEGFA expression. Sci. Rep. 6: 39429.
- Chiefari, E., et al. 2018. Cross-talk among HMGA1 and Fox01 in control of nuclear Insulin signaling. Sci. Rep. 8: 8540.
- Arcidiacono, B., et al. 2018. HMGA1 is a novel transcriptional regulator of the FoxO1 gene. Endocrine 60: 56-64.
- Zhu, Y., et al. 2022. Apelin-mediated deamidation of HMGA1 promotes tumorigenesis by enhancing SREBP1 activity and lipid synthesis. Cancer Sci. E-published.

#### **RESEARCH USE**

For research use only, not for use in diagnostic procedures.

## **PROTOCOLS**

See our web site at www.scbt.com for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3801 fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com